Pulling SEC filings + quote and writing the call…

PACS Group, Inc.
Last earnings -5.0% on 2026-05-11
Fast-growing skilled-nursing roll-up with 20% ROE, but unremediated revenue-recognition material weaknesses make the numbers hard to trust.
Sources: SEC EDGAR (CIK 0002001184, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/21/2026, 8:49:20 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Middling fundamentals offset by an attractive price (~17% below fair value) — worth a look on the value angle.
PACS Group is a rapid-growth post-acute care roll-up: it operated 321 skilled-nursing/assisted-living facilities across 17 states with operational capacity for 35,379 patients as of December 31, 2025. The growth record is striking -- revenue compounded from $2.40B (2022) to $5.29B in FY2025 (+29.4%), operating income jumped 151.6% to $310M and net income rebounded 243.5% to $192M (EPS $1.22, +221.1%). Returns are high at 20.2% ROE, the cash conversion is real ($404M operating cash flow, +10.0%), and debt is modest -- $245M long-term debt and $4.46M current portion against $197M of cash -- with the business funded largely through long-term triple-net leases (averaging 13 years). The acquire-and-improve model is showing results: mature facilities carry a 4.4 QM Star rating and 95% occupancy.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $2.40B | $3.11B | $4.09B | $5.29B |
| Gross profit | — | — | — | — |
| Operating income | $229M | $208M | $123M | $310M |
| Net income | $150M | $113M | $55.8M | $192M |
| Diluted EPS | $1.17 | $0.88 | $0.38 | $1.22 |
| Net margin | 6.3% | 3.6% | 1.4% | 3.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1074 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 10 sales
| 2026-06-17 | Hancock Mark Co Fndr; Exec V Chair | Sell | 60.4K @ $35.28 | $2.13M |
| 2026-06-17 | Hancock Mark Co Fndr; Exec V Chair | Sell | 3.32K @ $35.75 | $119K |
| 2026-06-16 | Hancock Mark Co Fndr; Exec V Chair | Sell | 83.1K @ $35.90 | $2.98M |
| 2026-06-15 | Hancock Mark Co Fndr; Exec V Chair | Sell | 134K @ $36.23 | $4.86M |
| 2026-06-15 | Hancock Mark Co Fndr; Exec V Chair | Sell | 19.1K @ $37.05 | $709K |
| 2026-06-15 | Hancock Mark Co Fndr; Exec V Chair | Sell | 23.00 @ $37.88 | $871.14 |
| 2026-06-10 | Conway Patrick Hugh Director | Award | 4.66K | |
| 2026-06-10 | LEAVITT TAYLOR S. Director | Award | 4.66K | |
| 2026-06-10 | Millard Jacqueline Director | Award | 4.66K | |
| 2026-06-10 | Dilsaver Evelyn S Director | Award | 4.66K | |
| 2026-05-18 | MITCHELL JOHN TODD Chief Legal Officer & Sec. | Sell | 24.1K @ $37.04 | $892K |
| 2026-05-18 | MITCHELL JOHN TODD Chief Legal Officer & Sec. | Sell | 3.30K @ $38.01 | $125K |